Tom Holgate

BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom.

Part of BenevolentAI SA, BenevolentAI Technology Ltd. is a leading, clinical-stage AI-enabled drug discovery and British development company. Founded in 2005, the company is based in London, UK. From target identification through to clinical development, their AI-enabled Benevolent Platform™ augments scientific ingenuity, with the goal of improving the probability of clinical success. The company uses AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug. The company uses machine learning to generate new insights into the underlying causes of disease and capture these insights in their knowledge graph to support drug discovery and development. In 2022, they refined and formalized their approach to sustainability, under the direction of the newly established environmental, social and governance (ESG) governance structure and teams.

BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom.